Investment Management Corp of Ontario Has $1.36 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Investment Management Corp of Ontario trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 76.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,690 shares of the company's stock after selling 8,592 shares during the period. Investment Management Corp of Ontario's holdings in IDEXX Laboratories were worth $1,359,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in IDEXX Laboratories by 0.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock worth $379,875,000 after buying an additional 2,463 shares during the last quarter. American Century Companies Inc. grew its stake in IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock worth $274,179,000 after buying an additional 177,226 shares during the last quarter. International Assets Investment Management LLC grew its stake in IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after buying an additional 527,460 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in IDEXX Laboratories by 13.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock worth $249,855,000 after buying an additional 59,519 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in IDEXX Laboratories by 4.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company's stock worth $205,163,000 after buying an additional 15,521 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

IDXX stock traded up $8.20 during trading hours on Friday, hitting $435.69. 551,918 shares of the stock traded hands, compared to its average volume of 511,214. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a market cap of $35.68 billion, a P/E ratio of 42.01, a P/E/G ratio of 3.95 and a beta of 1.37. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The stock has a 50-day simple moving average of $445.99 and a 200 day simple moving average of $475.13.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period in the prior year, the business posted $2.53 earnings per share. IDEXX Laboratories's revenue was up 6.6% compared to the same quarter last year. Equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.11% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research note on Monday. Piper Sandler reissued a "neutral" rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. Barclays decreased their price target on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Finally, Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday. They issued an "outperform" rating and a $500.00 price target for the company. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $546.56.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.